Zimbabwe has turned down a substantial American health deal worth $367m (272 million pounds) over five years due to Washington's demand for confidential information.
This move became public following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman has since stated that the United States was requesting genetic material for scientific study and commercial purposes but was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to secure a deal suitable to all parties so the nation's vital HIV programme can be sustained.
Broader Context
This development follows a comparable situation in Kenya, where a high court halted a related health funding agreement following legal challenges were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump stated its spending was "wasteful" and his government was seeking government-to-government deals to enhance openness and responsibility.
According to statements, Sixteen African countries have so far signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our people if a new disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one deals were undermining systems already set up via the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is designed to guarantee that when a country provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent collaboration might be arranged in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
A leading public health body said it understood the government's concerns, but recommended that negotiations must proceed given that much of the country's Aids initiatives relied on international support.
"In cases where specific concerns exist, such as those involving information security or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it commented.
The situation emphasises the ongoing challenges between receiving much-needed foreign assistance and protecting local interests in an increasingly data-driven world.